...
search icon
qttb-img

Q32 Bio Inc, Common Stock

QTTB

NMQ

$2.435

+$0.02

(0.83%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$29.48M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
177.11K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.38 L
$53.79 H
$2.435

About Q32 Bio Inc, Common Stock

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameQTTBSectorS&P500
1-Week Return-9.02%0.4%1.6%
1-Month Return-28.82%2.74%1.66%
3-Month Return-91.68%3.68%3.86%
6-Month Return-93.78%-4.81%9.59%
1-Year Return-83.68%0.88%23.47%
3-Year Return-94.83%15.1%42.73%
5-Year Return-99.28%40.72%81.29%
10-Year Return-99.28%104.96%192.65%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue1.67M2.70M33.97M6.65M1.16M[{"date":"2019-12-31","value":4.9,"profit":true},{"date":"2020-12-31","value":7.95,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":19.58,"profit":true},{"date":"2023-12-31","value":3.4,"profit":true}]
Cost of Revenue--9.54M2.60M578.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":27.23,"profit":true},{"date":"2023-12-31","value":6.06,"profit":true}]
Gross Profit1.67M2.70M24.43M4.05M578.00K[{"date":"2019-12-31","value":6.82,"profit":true},{"date":"2020-12-31","value":11.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.59,"profit":true},{"date":"2023-12-31","value":2.37,"profit":true}]
Gross Margin100.00%100.00%71.91%60.92%50.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":71.91,"profit":true},{"date":"2022-12-31","value":60.92,"profit":true},{"date":"2023-12-31","value":50,"profit":true}]
Operating Expenses105.29M124.06M36.69M45.88M92.68M[{"date":"2019-12-31","value":84.87,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":29.58,"profit":true},{"date":"2022-12-31","value":36.98,"profit":true},{"date":"2023-12-31","value":74.71,"profit":true}]
Operating Income(109.94M)(130.26M)(36.69M)(39.23M)(92.10M)[{"date":"2019-12-31","value":-10994300000,"profit":false},{"date":"2020-12-31","value":-13026300000,"profit":false},{"date":"2021-12-31","value":-3669300000,"profit":false},{"date":"2022-12-31","value":-3922500000,"profit":false},{"date":"2023-12-31","value":-9210200000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(103.92M)(128.69M)(37.02M)(42.75M)(87.08M)[{"date":"2019-12-31","value":-10391600000,"profit":false},{"date":"2020-12-31","value":-12869399900,"profit":false},{"date":"2021-12-31","value":-3701700000,"profit":false},{"date":"2022-12-31","value":-4274700000,"profit":false},{"date":"2023-12-31","value":-8708000000,"profit":false}]
Income Taxes-(1.00)547.00K62.00K25.88M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":2.11,"profit":true},{"date":"2022-12-31","value":0.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations--(37.56M)(42.81M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3756400000,"profit":false},{"date":"2022-12-31","value":-4280900000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(103.92M)(128.69M)(37.56M)(42.81M)(112.96M)[{"date":"2019-12-31","value":-10391600000,"profit":false},{"date":"2020-12-31","value":-12869399900,"profit":false},{"date":"2021-12-31","value":-3756400000,"profit":false},{"date":"2022-12-31","value":-4280900000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}]
EPS (Diluted)(44.48)(50.54)(30.33)(1.78)(30.45)[{"date":"2019-12-31","value":-4447.72,"profit":false},{"date":"2020-12-31","value":-5053.78,"profit":false},{"date":"2021-12-31","value":-3032.57,"profit":false},{"date":"2022-12-31","value":-178.48,"profit":false},{"date":"2023-12-31","value":-3044.98,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

QTTB
Cash Ratio 6.19
Current Ratio 6.53

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

QTTB
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

QTTB
Debt Ratio Lower is generally better. Negative is bad. 0.82
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.18

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

QTTB
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 16.61
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Q32 Bio Inc share price today?

Q32 Bio Inc (QTTB) share price today is $2.435

Can Indians buy Q32 Bio Inc shares?

Yes, Indians can buy shares of Q32 Bio Inc (QTTB) on Vested. To buy Q32 Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QTTB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Q32 Bio Inc be purchased?

Yes, you can purchase fractional shares of Q32 Bio Inc (QTTB) via the Vested app. You can start investing in Q32 Bio Inc (QTTB) with a minimum investment of $1.

How to invest in Q32 Bio Inc shares from India?

You can invest in shares of Q32 Bio Inc (QTTB) via Vested in three simple steps:

  • Click on Sign Up or Invest in QTTB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Q32 Bio Inc shares
What is Q32 Bio Inc 52-week high and low stock price?

The 52-week high price of Q32 Bio Inc (QTTB) is $53.79. The 52-week low price of Q32 Bio Inc (QTTB) is $2.38.

What is Q32 Bio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Q32 Bio Inc (QTTB) is 16.61

What is the Market Cap of Q32 Bio Inc?

The market capitalization of Q32 Bio Inc (QTTB) is $29.48M

What is Q32 Bio Inc’s stock symbol?

The stock symbol (or ticker) of Q32 Bio Inc is QTTB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top